|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
230,290,000 |
Market
Cap: |
138.17(K) |
Last
Volume: |
11,847,187 |
Avg
Vol: |
11,814,278 |
52
Week Range: |
$0.0001 - $0.066 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Endo International is a holding company. Through its subsidiaries, Co. is engaged in specialty pharmaceuticals. Co.'s segments are: Branded Pharmaceuticals, which includes branded products to treat and manage conditions in the areas of urology, orthopedics, endocrinology and bariatrics, among others; Sterile Injectables, which consists of branded sterile injectable products; Generic Pharmaceuticals, which includes generic product families that treat and manage a range of medical conditions; and International Pharmaceuticals, which includes products serving therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, oncology and transplantation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sweeney Edward J |
Principal Accounting Officer |
|
2011-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,110 |
1,110 |
|
- |
|
Gergel Ivan |
EVP, Research & Development |
|
2011-02-24 |
4 |
AS |
$33.59 |
$528,774 |
D/D |
(15,742) |
0 |
|
- |
|
Gergel Ivan |
EVP, Research & Development |
|
2011-02-24 |
4 |
OE |
$20.61 |
$324,443 |
D/D |
15,742 |
15,742 |
|
- |
|
Gergel Ivan |
EVP, Research & Development |
|
2011-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,316 |
13,316 |
|
- |
|
Mchugh Julie |
Chief Operating Officer |
|
2011-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,745 |
15,745 |
|
- |
|
Levin Alan G |
EVP, Chief Financial Officer |
|
2011-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,368 |
16,368 |
|
- |
|
Manogue Caroline B |
Exec. V.P., CLO & Secy |
|
2011-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,732 |
11,732 |
|
- |
|
Holveck David |
President & CEO |
|
2011-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,913 |
51,913 |
|
- |
|
Sweeney Edward J |
Principal Accounting Officer |
|
2011-02-21 |
4 |
S |
$32.34 |
$22,476 |
D/D |
(695) |
0 |
|
- |
|
Sweeney Edward J |
Principal Accounting Officer |
|
2011-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
695 |
695 |
|
- |
|
Sweeney Edward J |
Principal Accounting Officer |
|
2011-02-19 |
4 |
S |
$32.34 |
$37,838 |
D/D |
(1,170) |
0 |
|
- |
|
Sweeney Edward J |
Principal Accounting Officer |
|
2011-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,170 |
1,170 |
|
- |
|
Spengler William |
Director |
|
2010-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
854 |
14,771 |
|
- |
|
Montague William P |
Director |
|
2010-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
406 |
10,385 |
|
- |
|
Scodari Joseph C |
Director |
|
2010-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
252 |
15,412 |
|
- |
|
Levin Alan G |
EVP, Chief Financial Officer |
|
2010-12-13 |
4/A |
OE |
$20.09 |
$99,988 |
D/D |
4,977 |
11,554 |
|
- |
|
Kimmel Roger H |
Director |
|
2010-12-10 |
4 |
S |
$36.55 |
$502,234 |
D/D |
(13,741) |
191,853 |
|
- |
|
Kimmel Roger H |
Director |
|
2010-12-10 |
4 |
OE |
$11.00 |
$245,391 |
D/D |
13,741 |
205,594 |
|
- |
|
Hutson Nancy J |
Director |
|
2010-12-07 |
4 |
B |
$36.38 |
$36,380 |
I/I |
1,000 |
1,000 |
2.1 |
- |
|
Levin Alan G |
EVP, Chief Financial Officer |
|
2010-12-07 |
4 |
OE |
$16.51 |
$374,500 |
D/D |
21,604 |
11,554 |
|
- |
|
Levin Alan G |
EVP, Chief Financial Officer |
|
2010-12-07 |
4 |
S |
$36.04 |
$599,237 |
D/D |
(16,627) |
6,577 |
|
- |
|
Gergel Ivan |
EVP, Research & Development |
|
2010-12-03 |
4 |
S |
$36.53 |
$2,031,178 |
D/D |
(55,603) |
0 |
|
- |
|
Gergel Ivan |
EVP, Research & Development |
|
2010-12-03 |
4 |
OE |
$19.93 |
$1,235,418 |
D/D |
55,603 |
55,603 |
|
- |
|
Hyatt Michael |
Director |
|
2010-12-03 |
4 |
S |
$36.43 |
$364,300 |
D/D |
(10,000) |
247,605 |
|
- |
|
Hyatt Michael |
Director |
|
2010-12-03 |
4 |
OE |
$6.88 |
$68,800 |
D/D |
10,000 |
257,605 |
|
- |
|
825 Records found
|
|
Page 10 of 33 |
|
|